@article{discovery10182522, publisher = {MDPI AG}, note = {{\copyright} 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).}, journal = {International Journal of Molecular Sciences}, month = {November}, title = {Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population}, number = {21}, volume = {24}, year = {2023}, author = {Dalbeni, A and Garbin, M and Zoncap{\`e}, M and Romeo, S and Cattazzo, F and Mantovani, A and Cespiati, A and Fracanzani, AL and Tsochatzis, E and Sacerdoti, D and Mantovani, A and Lombardi, R}, url = {https://doi.org/10.3390/ijms242115837}, abstract = {Glomerular hyperfiltration (GH) is an increase in the glomerular filtration rate, possibly progressing to chronic kidney disease (CKD). Metabolic-associated steatotic liver disease (MASLD) is linked to an increased risk of CKD, especially if fibrosis is present; however, the association between GH and MASLD has not been explored. To evaluate GH prevalence in MASLD and its possible correlation with liver fibrosis. 772 consecutive patients with ultrasound MASLD (mean age 47.3 {$\pm$} 8.9 years, 67.1\% males) were enrolled. GH was defined as estimated glomerular filtration rate (eGFR) greater than the upper quartile of values in the cohort. Liver stiffness measurement (LSM) by FibroScan {$\ge$} 7.2 kPa suggested liver fibrosis. GH was present in 20\% of patients, liver fibrosis in 30\%. In total, 53.4\% of the cohort was obese, 40.9\% hypertensive, 36.3\% diabetic and 70.8\% dyslipidaemic. GH patients compared to non-GH were significantly younger (38.4 {$\pm$} 8.3 vs. 49.5 {$\pm$} 7.7, p {\ensuremath{<}} 0.001), with higher prevalence of LSM {\ensuremath{>}} 7.2 kPa (35.5\% vs. 29\%, p {\ensuremath{<}} 0.001), without any difference in metabolic comorbidities. In multivariate analysis, age (OR 0.85, CI 95\% 0.82-0.87) and significant fibrosis (OR 1.83; CI 95\%1.10-3.03) remained independently associated with GH, regardless of the presence of metabolic alterations and nephrotoxic drugs. GH, an early marker of renal damage, is highly prevalent in MASLD and is associated with hepatic fibrosis. GH may be considered an early marker of both liver and renal disease and its recognition could prompt the management of risk factors aimed at preventing the progression of both hepatic and renal disease.}, issn = {1661-6596}, keywords = {FibroScan, MASLD, glomerular filtration rate, hepatic fibrosis, kidney disease, steatotic liver disease, Male, Humans, Adult, Middle Aged, Female, Fatty Liver, Liver Cirrhosis, Risk Factors, Renal Insufficiency, Chronic} }